ArticleRSC advances2018

Livin participates in resistance to trastuzumab therapy for breast cancer through ERK1/2 and AKT pathways and promotes EMT-like phenotype.

Fan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.